AI-powered discovery of a novel p53-Y220C reactivator

Front Oncol. 2023 Aug 1:13:1229696. doi: 10.3389/fonc.2023.1229696. eCollection 2023.

Abstract

Introduction: The p53-Y220C mutation is one of the most common mutations that play a major role in cancer progression.

Methods: In this study, we applied artificial intelligence (AI)-powered virtual screening to identify small-molecule compounds that specifically restore the wild-type p53 conformation from p53-Y220C. From 10 million compounds, the AI algorithm selected a chemically diverse set of 83 high-scoring hits, which were subjected to several experimental assays using cell lines with different p53 mutations.

Results: We identified one compound, H3, that preferentially killed cells with the p53-Y220C mutation compared to cells with other p53 mutations. H3 increased the amount of folded mutant protein with wild-type p53 conformation, restored its transcriptional functions, and caused cell cycle arrest and apoptosis. Furthermore, H3 reduced tumorigenesis in a mouse xenograft model with p53-Y220C-positive cells.

Conclusion: AI enabled the discovery of the H3 compound that selectively reactivates the p53-Y220C mutant and inhibits tumor development in mice.

Keywords: Y220C; apoptosis; artificial intelligence; mutant p53; small molecule inhibitors.

Grants and funding

YL is a CPRIT Scholar in Cancer Research supported by the Cancer Prevention and Research Institute of Texas (No. RR190043).